Antimicrobial Tools & Resources
People with cystic fibrosis (CF) have mucus build up in the lungs that make them susceptible to lung infections by bacteria, viruses and fungi. Over time, constant bacterial infections often lead to pulmonary exacerbations and permanent lung damage.
The main bacterium that affects people with CF is Pseudomonas aeruginosa and — while there are good treatments available — various drug-resistant strains have developed that make treatment difficult. Access to antimicrobial tools can aid researchers in the discovery of new antiinfective treatments.
Certain research tools, such as clinical isolates of P. aeruginosa, Burkholderia. cepacia, and other bacterial strains can be obtained for CF research purposes.
On this page:
In vivo murine models to study anti-microbial agents in CF
Clinical isolates of P. aeruginosa (bacterial strains isolated from the lungs of people with CF) are recommended for research areas including new drug discovery, biofilm research, virulence studies, drug resistance studies, etc.
CF isolates of Staphylococcus aureus (including MRSA), Stenotrophomonas maltophilia and Achromobacter xylosoxidans also are available.
B. cepacia complex and other non-fermenting bacterial isolates can be requested from Dr. John LiPuma who maintains a bacterial repository for the CF clinical research community.
Following sequencing of the P. aeruginosa genome, an annotated database (Pseudomonas Genome Database) was constructed to serve as a central portal through which researchers may access high quality genome-associated information about P. aeruginosa and its potential drug/vaccine targets.
Moreover, Affymetrix genome microarrays were made available for understanding P. aeruginosa gene expression under many different conditions.